Signaling Pathway
Garetatug is a humanized monoclonal antibody designed to target and bind specifically to human Claudin-18 (CLDN18), a tight junction protein. By binding to CLDN18, Garetatug disrupts critical cell signaling pathways, thereby exerting antitumor effects. This antibody is utilized primarily in research focused on the mechanisms of tumor progression and therapeutic intervention.
重要通知：仅供研究使用。我们不向患者销售。
| Discription | Garetatug is a humanized monoclonal antibody designed to target and bind specifically to human Claudin-18 (CLDN18), a tight junction protein. By binding to CLDN18, Garetatug disrupts critical cell signaling pathways, thereby exerting antitumor effects. This antibody is utilized primarily in research focused on the mechanisms of tumor progression and therapeutic intervention. |
||
|---|---|---|---|
| Targets |
|
Calculate the dilution required to prepare a stock solution. This equation is commonly abbreviated as: C1V1 = C2V2
